Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

10.83 -0.18 (-1.63%)
Streaming Delayed Price Updated: 3:20 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Capricor Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Forecasting The Future: 5 Analyst Projections For Capricor Therapeutics
Via Benzinga
A Look Ahead: Capricor Therapeutics's Earnings Forecast
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock
Via Benzinga
Decoding 12 Analyst Evaluations For Capricor Therapeutics
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
From Pomerantz LLP
Via GlobeNewswire
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns. 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For November 13, 2024
Via Benzinga
Earnings Preview For Capricor Therapeutics
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic
The U.S. FDA stated that its review committee has identified no significant deficiencies and is on track to make a decision on the application by its deadline of the end of August. 
Via Stocktwits
Topics Economy Government
Exposures Economy Political Product Safety
uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Capricor Therapeutics’ CAP-1002: Regulatory Progress, Clinical Outcomes & Investment Outlook
If CAP-1002 (Deramiocel) is approved on schedule, deramiocel would become the first therapy indicated specifically for DMD-associated cardiomyopathy, addressing a critical unmet need. The StealthX(tm)... 
Via Talk Markets
Topics Stocks / Equities
FDA Advisory Committee Shakeup and Implications for Capricor Therapeutics
Don't be scared off up by the recent Trump FDA overhaul. The changes are very positive for Capricor Therapeutics moving forward (2025–2028). 
Via Talk Markets
Topics Government Stocks / Equities
Exposures Political Product Safety
Robinhood, Couchbase And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Capricor Therapeutics Stock Surges After Q4 Results Beat Estimates: Retail Gets More Bullish
The company said its available cash, cash equivalents, and marketable securities will be sufficient to cover the expenses and capital requirements into 2027. 
Via Stocktwits
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
Via Benzinga
A Glimpse Into The Expert Outlook On Capricor Therapeutics Through 4 Analysts
Via Benzinga
Earnings Scheduled For March 19, 2025
Via Benzinga
Capricor Therapeutics’ Retail Chatter Explodes On Stocktwits After FDA Grants Priority Review For DMD Therapy
The health agency has accepted Capricor's Biologics License Application for full approval of deramiocel as a treatment for Duchenne muscular dystrophy cardiomyopathy. 
Via Stocktwits
Exposures Product Safety
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition
FDA grants Priority Review to Capricor's deramiocel for Duchenne cardiomyopathy, setting an August 2025 decision date with no identified review issues. 
Via Benzinga
Exposures Product Safety
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
America's Car-Mart Posts Upbeat Sales, Joins Methode Electronics, Verint Systems, Brown-Forman And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Space, Biotech, And More: Today’s Hottest Stocks To Watch
Today’s macro environment reflects a strong risk-on sentiment, fueled by a notable rally in Bitcoin, which has surged past the $90,000 threshold. 
Via Talk Markets
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.